Abstract:Traditional analytical epidemiology is directed at identifying the association between risk factors and occurrence of disease by using crude exposure data derived from questionnaires or clinical measures, and taking clinical disease as the end point. With the rapid development in molecular biology and laboratory methods, it is now possible to use biomarkers which are capable of identifying molecular events for epidemiologic research. This improved sensitivity enables us to develop a mechanistic understanding of disease causation: a step closer to the unravelling of the "black box" of traditional epidemiology. Biomarkers may be classified as internal indicators of exposure (biomarkers of exposure), indicators of preclinical adverse effect (biomarkers of effect) or indicators of an intrinsic or acquired susceptibility to disease (biomarkers of susceptibility). Biomarkers provide a better definition of exposure and disease status and consequently they could help to reduce misclassification bias in both exposure and disease, reduce the follow-up time in prospective studies, as well as identify possible interactions between risk factors on disease occurrence. However, a biomarker needs to be validated and its distribution in large populations described before it can be used profitably for aetiologic research. Also, the use of biomarkers in epidemiologic research raises other interesting epidemiological and statistical issues like confounding, effect modification and the analysis of repeated measurements. Molecular epidemiology is a multidisciplinary endeavour which comprises molecular biology, epidemiology and biostatistics. Clearly then, to carry out research in this field profitably, the molecular biologist, epidemiologist and biostatistician must acquire not only expertise in their respective fields, but also an integrated understanding of all three fields. The molecular biologist is not merely a laboratory bench worker; the epidemiologist, a field data-collector and the biostatistician, a number cruncher. They must work together to pry open the "black box" to gain a greater insight into how risk factors operate to initiate disease onset and ultimately to make use of this knowledge base to implement preventive measures.

Cancer Molecular Epidemiology and Tumor Markers

Molecular Imaging of the Tumor Microenvironment☆

Molecular epidemiology: recent advances and future directions

Molecular Imaging in Tracking Tumor Stem-Like Cells

Tumor biomarkers for diagnosis, prognosis and targeted therapy

Emerging Non-Invasive Detection Methodologies For Lung Cancer

Molecular Epidemiology, Cancer-Related Symptoms, and Cytokines Pathway

Molecular characteristics and prognostic role of EPHA2 in human tumors via pan-cancer analysis

Molecular epidemiology: issues in study design and statistical analysis

Molecular Biomarkers in Cancer

[Multi-omics approaches for revealing the etiology of cancer: from genomics, exposomics, metabolomics to system epidemiology].

Molecular Toxicology and Cancer Prevention

The Cancer Secretome: a Reservoir of Biomarkers.

Tumor Promoters and Opportunities for Molecular Cancer Prevention

Cancer as microenvironmental, systemic and environmental diseases: opportunity for transdisciplinary microbiomics science

The outpost against cancer: universal cancer only markers

Research and Clinical Applications of Molecular Biomarkers in Gastrointestinal Carcinoma (Review)

Genetic and Phenotypic Markers of Tumors

Proteomics, Pathway Array and Signaling Network-Based Medicine in Cancer

[Molecular Markers of Gastrointestinal Tumors and Individualized Treatment].

Microbiota in cancer: molecular mechanisms and therapeutic interventions